Active Ingredient History

NOW
  • Now
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow intravenous infusion. Biosimilars of Rituxan include Blitzima, Riabni, Ritemvia, Rituenza, Rixathon, Ruxience, and Truxima.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$49.1590 - $3421.9100

Australia

$150.7455 - $1359.3025
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( hyaluronidase (human recombinant) (Hylenex), rituximab (rituxan) - other name: rituximab and hyaluronidase human )
abp 798 | acellbia | anticd20 | aurixim | chimeric anti-cd20 monoclonal antibody | cmab304 | drl_ri | ib301 | ibi301 | idec-102 | idec-c2b8 | jhl1101 | mabthera | mabthera rituxan | r-105 idec-102 | rg-105 | ritixumab | rituxan | rituximab | rituximab-abbs | t-cells rituximab + il-2 | tl011 | ub-921

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue